PhaseV
Boston, United States · Artificial Intelligence, Biotechnology, Health Care
PhaseV is leveraging cutting-edge algorithms such as reinforcement learning and causal ML for adaptive trial design and closed-loop execution, in order to improve trial success rate while maximizing resource and time efficiency. Our novel methodology and advanced technology also enable the detection of hidden signals in data while analyzing clinical trial results and extracting actionable insights
Key facts
- Headquarters
- Boston, United States
- Employees
- 32
- Industries
- Artificial Intelligence, Biotechnology, Health Care
- Status
- Private
- Website
- phasevtrials.com
- Company page
Recent activity at PhaseV
- : PhaseV launches BonV, an agentic AI orchestrator designed to assist clinical teams in making informed decisions.
- : PhaseV launches the ClinOps AI platform to enhance clinical trial operations with advanced data analytics.
- : PhaseV has secured $50M in a Series A funding round, co-led by Accel and Insight Partners, to enhance its AI platform for clinical development.
- : PhaseV Launches ML-Driven Solution to Enhance Lupus Research Through Collaboration with University Health Network
- : PhaseV Appoints Hamza Sheikh as Head of Business Development
PhaseV funding history
| Date | Round | Amount |
|---|---|---|
| May 2025 | Series A | $50.0M |
Leadership
- Elad Berkman, Founder
- Raviv Pryluk, Chief Executive Officer
- Hamza Sheikh, Head of Business Development
Verified email and direct lines for PhaseV’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
PhaseV in the news
- PhaseV Demonstrates How AI-Driven Site Selection and Real-Time Analytics Reduce Recruitment Uncertainty and Accelerate IBD Clinical Trials - PR Newswire (Jan 22, 2026)
- New PhaseV Survey Reveals 88% of Sponsors Face Five or More Weeks of Delay in Trial Reporting and Data Workflows, Amid Vendor Fragmentation and Repeated Protocol Amendments - PR Newswire (Aug 17, 2026)
- PhaseV Bringing Integrated AI for Faster Clinical Trials to the Global Stage - PR Newswire (Mar 26, 2026)
- PhaseV Lands $50M Series A to Supercharge AI for Clinical Development, Backed by Top VCs and Trusted by Leading Pharma Clients - PR Newswire (May 13, 2025)
Companies similar to PhaseV
- Positron · Artificial Intelligence, Biotechnology, Health Care, Machine Learning, Medical
- Medow Health · Artificial Intelligence, Biotechnology, Health Care, Machine Learning, Medical
- SmartAlpha · Artificial Intelligence, Biotechnology, Health Care, Machine Learning, Medical
- Vektor Medical · Artificial Intelligence, Biotechnology, Health Care, Machine Learning, Medical
- Healthplus.ai · Artificial Intelligence, Biotechnology, Health Care, Machine Learning, Medical
About PhaseV: questions and answers
What does PhaseV do?
PhaseV is leveraging cutting-edge algorithms such as reinforcement learning and causal ML for adaptive trial design and closed-loop execution, in order to improve trial success rate while maximizing resource and time efficiency. Our novel methodology and advanced technology also enable the detection of hidden signals in data while analyzing clinical trial results and extracting actionable insights
Where is PhaseV headquartered?
PhaseV is headquartered in Boston, United States.
How many employees does PhaseV have?
PhaseV has about 32 employees.
Has PhaseV raised funding?
Yes. Fundz has recorded 1 funding event for PhaseV. The most recent, Series A of $50.0M, was in May 2025.
Who leads PhaseV?
Elad Berkman is a Founder at PhaseV.
What is the latest news on PhaseV?
On Nov 03, 2026, PhaseV launches BonV, an agentic AI orchestrator designed to assist clinical teams in making informed decisions.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy